Fertility and Sterility
Volume 94, Issue 5 , Pages 1639-1646.e1 , October 2010

In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells

Presented at the 10th World Congress on Endometriosis 2008, organized by the Australian Gynaecological Endoscopy Society, Melbourne, Australia, March 11–14, 2008, P-250, p. 113.

  • Indu Sharma, M.Sc.

      Affiliations

    • Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
    • ,
  • Veena Dhawan, Ph.D.

      Affiliations

    • Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
    • Corresponding Author InformationReprint requests: Veena Dhawan, Ph.D., Associate Professor, Department of Experimental Medicine and Biotechnology, Research Block “B” Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India (FAX: 91-172-2744401).
    • ,
  • Nitin Mahajan, Ph.D.

      Affiliations

    • Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
    • ,
  • Subhash Chand Saha, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
    • ,
  • Lakhbir Kaur Dhaliwal, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Received 1 August 2009 ,Revised 19 September 2009 ,Accepted 2 October 2009.

References 

  1. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 2005;57:359–383
  2. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, et al. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001;2:544–551
  3. Esfandiari N, Ai J, Nazemian Z, Javed MH, Gotlieb L, Casper RF. Expression of glycodelin and cyclooxygenase-2 in human endometrial tissue following three dimensional culture. Am J Reprod Immunol. 2007;57:49–54
  4. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update. 2000;6:45–55
  5. Halis G, Arici A. Endometriosis and inflammation in infertility. Ann NY Acad Sci. 2004;1034:300–315
  6. Weiss G, Goldsmith LT, Taylor RN, Bellet D, Taylor HS. Inflammation in reproductive disorders. Reprod Sci. 2009;16:216–229
  7. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is inhibited by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000;275:25781–25790
  8. Bulun SE. Mechanisms of disease: endometriosis. N Engl J Med. 2009;360:268–279
  9. Pietzsch J, Hoppmann S. Human S100A12: a novel key player in inflammation?. Amino Acids. 2009;36:381–389
  10. Mahajan N, Malik N, Bahl A, Dhawan V. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with premature coronary artery disease. Atherosclerosis. Published online June 11, 2009.
  11. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone?. Diabetes Care. 2003;26:2442–2450
  12. Panunti B, Fonseca V. Effects of PPAR-gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascul Pharmacol. 2006;45:29–35
  13. Wójcicka G. Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw. 2007;61:736–759
  14. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPAR-γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110:923–932
  15. Peeters LLH, Vigne JL, Tee MK, Zhao D, Waite LL, Taylor RN. PPAR-gamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis. 2006;8:373–379
  16. Hornung D, Waite LL, Ricke EA, Bentzien F, Wallwiener D, Taylor RN. Nuclear peroxisome proliferator-activated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis. J Clin Endocrinol Metab. 2001;86:3108–3114
  17. Wanichkul T, Han S, Huang RP, Sidell N. Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. Fertil Steril. 2003;79(Suppl 1):763–769
  18. Piotrowski PC, Kwintkiewicz J, Rzepczynska IJ, Seval Y, Cakmak H, Arici A, et al. Statins inhibit growth of human endometrial stromal cells independently of cholesterol availability. Biol Reprod. 2006;75:107–111
  19. Esfandiari N, Khazaei M, Ai J, Bielecki R, Gotlieb L, Ryan E, et al. Effect of a statin on an in vitro model of endometriosis. Fertil Steril. 2007;87:257–262
  20. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes. Inflamm Res. 2002;51:58–62
  21. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, et al. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl–CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem. 2005;280:22212–22221
  22. Ye P, Sheng L, Zhang C, Liu Y. Atorvastatin attenuating downregulation of peroxisome proliferator activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J Pharm Pharmaceut Sci. 2006;9:365–375
  23. Guan JZ, Tamasawa N, Murakami H, Matsui J, Tanabe J, Matsuki K, et al. HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. J Atheroscler Thromb. 2008;15:20–25
  24. Sharma I, Dhaliwal LK, Saha SC, Sangwan S, Dhawan V. Role of 8-isoPGF2α and 25-hydroxycholesterol in the pathophysiology of endometriosis. Fertil Steril. Published online March 24, 2009.
  25. American Society for Reproductive Medicine . Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67:817–821
  26. Freshney RI. Culture of animal cells: a manual of basic technique. 4th ed.. Hoboken, NJ: Wiley-Liss; 2000;321
  27. Mahajan N, Bahl A, Dhawan V. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol. Published online June 11, 2009.
  28. Rogers PA, Donoghue JF, Walter LM, Girling JE. Endometrial angiogenesis, vascular maturation, and lymphangiogenesis. Reprod Sci. 2009;16:147–151
  29. Kyama CM, Mihalyi A, Simsa P, Mwenda JM, Tomassetti C, Meuleman C, et al. Non-steroidal targets in the diagnosis and treatment of endometriosis. Curr Med Chem. 2008;15:1006–1017
  30. Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss. 2005;98:661–666
  31. Kinlay S. Potential vascular benefits of statins. Am J Med. 2005;118:62S–67S
  32. Bell SC, Jackson JA, Ashore J, Zhu HH, Tseng L. Regulation of insulin-like growth factor-binding protein-1 synthesis and secretion by progestin and relaxin in long term cultures of human endometrial stromal cells. J Clin Endocrinol Metab. 1991;72:1014–1019
  33. Chan K, Spencer EM. General aspects of insulin-like growth factor binding proteins. Endocrine. 1997;7:95–97
  34. Fowler DJ, Nicolaides KH, Miell JP. Insulin like growth factor binding protein-1 (IGFBP-1): a multifunctional role in the human female reproductive tract. Hum Reprod. 2000;6:495–504
  35. Klemmt PAB, Carver JG, Kennedy SH, Koninckx PR, Mardon HJ. Stromal cells from endometriotic lesions and endometrium from women with endometriosis have reduced decidualization capacity. Fertil Steril. 2006;85:564–572
  36. Kim JG, Suh CS, Kim SH, Choi YM, Moon SY, Lee JY. Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs) and IGFBP-3 protease activity in the peritoneal fluid of patients with and without endometriosis. Fertil Steril. 2000;73:996–1000
  37. Hernández-Presa MA, Martín-Ventura JL, Ortego M, Gómez-Hernández A, Tuñón J, Hernández-Vargas P, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002;160:49–58
  38. Wu S, Duan S, Zhao S, Cai Y, Chen P, Fang X. Atorvastatin reduces lipopolysaccharide induced expression of cyclooxygenase-2 in human pulmonary epithelial cells. Respir Res. 2005;6:27–33
  39. Deng P, Zhao S, Dai H, Guan X, Huan H. Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and modulates the early inflammatory response. Clin Chem. 2006;52:300–303
  40. Loboda A, Jazwaa A, Jozkowicza A, Molema G, Dulak J. Angiogenic transcriptome of human microvascular endothelial cells: effect of hypoxia, modulation by atorvastatin. Vascul Pharmacol. 2006;44:206–214
  41. Oktem M, Esinler I, Eroglu D, Haberal N, Bayraktar N, Zeyneloglu HB, et al. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod. 2007;22:1474–1480
  42. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006;26:2716–2723
  43. Cilla DD, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996;60:687–695
  44. Honjo H, Tanaka K, Urabe M, Naitoh K, Ogino Y, Yamamoto T, et al. Menopause and hyperlipidemia: pravastatin lowers lipid levels without decreasing endogenous estrogens. Clin Ther. 1992;14:699–707
  45. Böhm M, Herrmann W, Wassmann S, Laufs U, Nickenig G. Does statin therapy influence steroid hormone synthesis?. Z Kardiol. 2004;93:43–48
  46. Mounsey AL, Wilgus A, Slawson DC. Diagnosis and management of endometriosis. Am Fam Physician. 2006;74:594–600
  47. Cahill DJ. What is the optimal management of infertility and minor endometriosis? Analysis and future prospects. Hum Reprod. 2002;17:1135–1140

 I.S. has nothing to disclose. V.D. has nothing to disclose. N.M. has nothing to disclose. S.C.S. has nothing to disclose. L.K.D. has nothing to disclose.

 Supported by the Department of Science and Technology, New Delhi, India (DO no. SR/SO/HS-86/2005).

PII: S0015-0282(09)03859-X

doi: 10.1016/j.fertnstert.2009.10.003

Fertility and Sterility
Volume 94, Issue 5 , Pages 1639-1646.e1 , October 2010

Article Tools

* Image Usage & Resolution